1169699-61-9

Basic information

• Product Name: 9-benzyl-4-oxa-1,9-diaza-spiro[5.5]undecan-2-one
• Synonyms: 9-benzyl-4-oxa-1,9-diaza-spiro[5.5]undecan-2-one
• CAS NO: 1169699-61-9
• Molecular Weight: 260.336
• Mol File: 1169699-61-9.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 9-benzyl-4-oxa-1,9-diaza-spiro[5.5]undecan-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 9-benzyl-4-oxa-1,9-diaza-spiro[5.5]undecan-2-one(1169699-61-9)
• EPA Substance Registry System: 9-benzyl-4-oxa-1,9-diaza-spiro[5.5]undecan-2-one(1169699-61-9)

Safety Data

• Hazardous Substances Data: 1169699-61-9(Hazardous Substances Data)

Upstream product

• 312928-52-2 (4-amino-1-benzyl-piperidin-4-yl)-methanol 
• 79-04-9 chloroacetyl chloride 
• 1391602-69-9 N-(1-benzyl-4-hydroxymethyl-piperidin-4-yl)-2-chloro-acetamide 
• 28936-94-9 8-benzyl-1,3,8-triaza-spiro[4.5]decane-2,4-dione 
• 39143-25-4 1-benzyl-4-amino-4-piperidinecarboxylic acid 
• 3612-20-2 1-phenylmethyl-4-piperidone 

Downstream Products

• 1160247-03-9 2-oxo-4-oxa-1,9-diaza-spiro[5.5]undecane-9-carboxylic acid tert-butyl ester 
• 1391602-71-3 1-methyl-4-oxa-1,9-diaza-spiro[5,5]undecan-2-one hydrochloride 

Relevant articles and documents

SALT INDUCIBLE KINASE INHIBITORS

The present application provides compounds that modulate the activity of one or more salt inducible kinases (SIKs). Pharmaceutical composition and methods of treating diseases associated with abnormal expression and/or activity of one or more SIKs are also provided.

1,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN

The present invention relates to compounds having dual pharmacological activity towards both the sigma (σ) receptor, and the μ-opiod receptor and more particularly to 1,9-diazaspiro undecane compounds having this pharmacological activity, to processes of

SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS

The invention relates to new substituted pyridinyl-pyrimidines of formula 1 wherein ring A is a five-membered saturated or unsaturated carbocyclic ring which optionally comprises one, two or three heteroatoms each independently from each other selected from the group N, S and O, wherein R1, R2, R4, R3, R5 and R6 are defined as in claim 1 and wherein ring A is further optionally substituted by one or two further substituents and the pharmaceutically acceptable salts, diastereomers, enantiomers, racemates, hydrates and solvates of the aforementioned compounds.